Stock listing
NASDAQ:RADX Radiopharm Theranostics Limited Stock
US listing (NASDAQ) of Radiopharm Theranostics Limited · home listing ASX:RAD
Follow Radiopharm Theranostics Limited into a list and get an email when it puts out news.
Share price · NASDAQ:RADX
$0.63 USD -0.04 (-6.3%)
Close on Nov 20, 2026
- Day range
- $0.63 – $0.716 USDNov 20, 2026
- Volume
- 12,982 sharesNov 20, 2026
- Market cap
- $9.20M USDAt the close on Nov 20, 2026 · price × 14.59M shares outstanding
- 52-week range
- $0.63 – $16.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $95,021 USDMedian day 40,400 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:RAD · Home | $0.0040 AUD | +0.0010 (+33.3%) | 1,666,666 | $0.0030 | $0.0040 | $0.0030 | $0.0030 | Close on Nov 20, 2026 |
| NASDAQ:RADX | $0.63 USD | -0.043 (-6.3%) | 12,982 | $0.716 | $0.716 | $0.63 | $0.673 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · NASDAQ:RADX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.959 | +0.07 | +7.9% | $0.92 | $1.08 | $0.90 | 79,200 | |
| $0.889 | +0.02 | +2.3% | $0.904 | $0.99 | $0.833 | 41,600 | |
| $0.869 | -0.021 | -2.4% | $0.908 | $1.04 | $0.82 | 369,500 | |
| $0.89 | -0.103 | -10.4% | $0.945 | $0.96 | $0.86 | 72,000 | |
| $0.993 | -0.087 | -8.1% | $1.09 | $1.09 | $0.97 | 38,300 | |
| $1.08 | -0.036 | -3.2% | $1.09 | $1.161 | $1.08 | 8,900 | |
| $1.116 | +0.166 | +17.5% | $0.98 | $1.12 | $0.951 | 37,600 | |
| $0.95 | +0.05 | +5.6% | $1.00 | $1.00 | $0.901 | 25,100 | |
| $0.90 | -0.096 | -9.6% | $0.95 | $0.951 | $0.90 | 25,100 | |
| $0.996 | -0.014 | -1.4% | $0.95 | $1.06 | $0.95 | 17,300 | |
| $1.01 | +0.06 | +6.3% | $1.074 | $1.074 | $0.999 | 32,500 | |
| $0.95 | -0.029 | -3.0% | $0.95 | $0.993 | $0.905 | 15,800 | |
| $0.979 | -0.011 | -1.1% | $0.96 | $1.01 | $0.90 | 14,400 | |
| $0.99 | +0.027 | +2.8% | $0.933 | $1.182 | $0.933 | 31,400 | |
| $0.963 | -0.067 | -6.5% | $1.01 | $1.14 | $0.963 | 12,900 | |
| $1.03 | -0.05 | -4.6% | $1.02 | $1.14 | $0.90 | 106,400 | |
| $1.08 | -0.04 | -3.6% | $1.12 | $1.15 | $1.011 | 65,900 | |
| $1.12 | -0.08 | -6.7% | $1.17 | $1.191 | $1.11 | 39,200 | |
| $1.20 | +0.09 | +8.1% | $1.07 | $1.33 | $1.01 | 143,100 | |
| $1.11 | -0.02 | -1.8% | $1.10 | $1.33 | $1.10 | 9,600 | |
| $1.13 | +0.02 | +1.8% | $1.10 | $1.24 | $1.06 | 65,800 | |
| $1.11 | -0.04 | -3.5% | $1.13 | $1.156 | $1.06 | 26,700 | |
| $1.15 | -0.03 | -2.5% | $1.18 | $1.19 | $1.10 | 42,400 | |
| $1.18 | -0.09 | -7.1% | $1.28 | $1.28 | $1.16 | 77,500 | |
| $1.27 | -0.15 | -10.6% | $1.39 | $1.40 | $1.00 | 82,300 | |
| $1.42 | -0.06 | -4.1% | $1.44 | $1.65 | $1.40 | 62,300 | |
| $1.48 | -0.14 | -8.6% | $1.48 | $1.55 | $1.40 | 48,000 | |
| $1.62 | +0.10 | +6.6% | $1.60 | $1.63 | $1.43 | 63,400 | |
| $1.52 | 0.00 | 0.0% | $1.54 | $1.60 | $1.47 | 42,900 | |
| $1.52 | -0.13 | -7.9% | $1.60 | $1.80 | $1.52 | 44,000 | |
| $1.65 | +0.078 | +5.0% | $1.57 | $1.68 | $1.441 | 37,600 | |
| $1.572 | -0.053 | -3.3% | $1.61 | $1.68 | $1.485 | 59,900 | |
| $1.625 | -0.025 | -1.5% | $1.65 | $1.69 | $1.49 | 35,700 | |
| $1.65 | +0.04 | +2.5% | $1.69 | $1.69 | $1.50 | 33,400 | |
| $1.61 | -0.04 | -2.4% | $1.73 | $1.75 | $1.60 | 36,000 | |
| $1.65 | -0.08 | -4.6% | $1.74 | $1.842 | $1.65 | 36,800 | |
| $1.73 | +0.06 | +3.6% | $1.70 | $1.91 | $1.70 | 66,500 | |
| $1.67 | +0.15 | +9.9% | $1.56 | $1.80 | $1.55 | 187,800 | |
| $1.52 | -0.49 | -24.4% | $2.00 | $2.00 | $1.50 | 163,300 | |
| $2.01 | +0.03 | +1.5% | $2.01 | $2.075 | $1.97 | 58,500 | |
| $1.98 | -0.08 | -3.9% | $2.06 | $2.088 | $1.98 | 37,600 | |
| $2.06 | -0.02 | -1.0% | $2.11 | $2.28 | $2.05 | 22,000 | |
| $2.08 | -0.04 | -1.9% | $2.15 | $2.47 | $2.05 | 73,800 | |
| $2.12 | +0.04 | +1.9% | $2.08 | $2.297 | $2.06 | 27,700 | |
| $2.08 | -0.075 | -3.5% | $2.05 | $2.145 | $2.05 | 7,900 | |
| $2.155 | -0.005 | -0.2% | $2.06 | $2.23 | $2.05 | 18,700 | |
| $2.16 | -0.11 | -4.8% | $2.27 | $2.30 | $2.05 | 11,000 | |
| $2.27 | -0.01 | -0.4% | $2.27 | $2.27 | $2.18 | 14,600 | |
| $2.28 | -0.13 | -5.4% | $2.37 | $2.442 | $2.185 | 48,700 | |
| $2.41 | +0.15 | +6.6% | $2.46 | $2.722 | $2.27 | 333,300 | |
| $2.26 | -0.06 | -2.6% | $2.18 | $2.327 | $2.044 | 106,800 | |
| $2.32 | -0.16 | -6.5% | $2.427 | $2.53 | $2.32 | 18,600 | |
| $2.48 | +0.04 | +1.6% | $2.42 | $2.537 | $2.34 | 34,852 | |
| $2.44 | 0.00 | 0.0% | $2.43 | $2.52 | $2.35 | 73,074 | |
| $2.44 | +0.15 | +6.6% | $2.355 | $2.522 | $2.30 | 48,800 | |
| $2.29 | -0.21 | -8.4% | $2.45 | $2.45 | $2.23 | 88,900 |
- Ticker
- NASDAQ:RADX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 15, 2026
RAD interim analysis at SNO26 on RAD101 Phase IIb data
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 38 slides
Latest news
RAD Alignment with US FDA for Development of RAD101
Nov 3, 2026
Closed $0.869 (-2.4%) on Nov 4, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 30, 2026
Closed $1.08 (-3.2%) on Oct 30, 2026
Notice of Annual General Meeting/Proxy Form
Oct 26, 2026
Closed $0.90 (-9.6%) on Oct 27, 2026
Radiopharm receives $8M advance on FY26 R&D tax incentive
Oct 26, 2026
Closed $0.996 (-1.4%) on Oct 26, 2026
Notification regarding unquoted securities - RAD
Oct 20, 2026
Closed $0.99 (+2.8%) on Oct 20, 2026
Notification of cessation of securities - RAD
Oct 20, 2026
Closed $0.99 (+2.8%) on Oct 20, 2026
Non-Compliance with Listing Rule 10.11
Oct 11, 2026
Closed $1.11 (-1.8%) on Oct 12, 2026
Radiopharm Theranostics Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 76 in the last 12 months · 168 in all · newest Nov 15, 2026 · oldest 2021
- Decks
- 28 decks · latest October 2026
Where Radiopharm Theranostics Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:RAD · Home listing | ASX | Australia | AUD |
| NASDAQ:RADX · This page | NASDAQ | United States | USD |
| OTC:RDPTF | OTC | United States | USD |
| BOATS:RADX | BOATS | United States | USD |
Valuation
EV/sales 4.8× against a median of 26.5×: 3rd lowest of 6 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $13.37M AUD
- P/E
- Loss
- EV/sales
- 4.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- −77.7%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Radiopharm Theranostics Limited · ASX:RAD | US$11.59M | US$8.85M | n/a | 4.8× | n/a | 0.7× | n/a | 0.0× | n/a |
| Xintela AB · OMXSTO:XINT | US$11.89M | US$11.82M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| BioCardia, Inc. · NASDAQ:BCDA | US$11.88M | US$10.22M | n/a | n/a | n/a | 14.2× | n/a | 0.7× | 0.42 |
| Pluri Inc. · NASDAQ:PLUR | US$11.85M | US$38.65M | n/a | 26.5× | n/a | n/a | n/a | n/a | 0.53 |
| Synlogic Inc · OTC:SYBX | US$11.76M | US$201,442 | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 0.50 |
| Imugene Ltd · ASX:IMU | US$11.74M | US$14.16M | n/a | n/a | n/a | 2.0× | n/a | 0.7× | n/a |
| Simris Group AB Class B · OMXSTO:SIMRIS_B | US$11.55M | US$19.55M | n/a | 144× | n/a | 154× | n/a | 117× | n/a |
| Aelis Farma SA · EURONEXT:AELIS | US$11.55M | US$9.09M | n/a | 4.0× | n/a | 4.5× | −308.7% | 1.9× | n/a |
| Dyadic International, Inc. · NASDAQ:DYAI | US$11.51M | US$12.03M | n/a | 3.9× | n/a | n/a | −226.9% | n/a | 1.12 |
| Psyence Biomedical Ltd. · NASDAQ:PBM | US$11.33M | US$4.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.90 |
| Medicenna Therapeutics Corp. · TSX:MDNA | US$11.26M | US$7.37M | n/a | n/a | n/a | 9.7× | n/a | 0.1× | 1.36 |
| Median of the others | US$11.64M | US$11.02M | 26.5× | 4.5× | −267.8% | 0.7× | 0.72 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.15 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.014 · 1 analyst
- Revenue, year to Jun 2027
- 1.06M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Riccardo Canevari | Managing Director and CEO |
| Barbara Lani | VP Quality Affairs |
| Donna Supko | VP Regulatory Affairs |
| Emily Love-Leon | VP Clinical Operations |
| Levente Meszaros | VP Preclinical and Translational Science |
| Melissa Thomas | VP Portfolio Program Lead |
| Sherin Al-Safadi | VP Medical and Corporate Affairs |
| Vimal Patel | VP CMC |
| Dimitris Voliotis | Chief Medical Officer |
| Hitesh Goel | Head of Project Management |
| Paul Hopper | Executive Chairman |
Board
| Director | Role |
|---|---|
| Paul Hopper | Executive Chairman |
| Hester Larkin | Non - Executive Director |
| Ian Turner | Non - Executive Director |
| Noel Donnelly | Non Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Jun 3, 2026 | −9.5% |
| Q2 2026 | Feb 26, 2026 | +4.5% |
| Quarter to Sep 30, 2025 | Dec 3, 2025 | −4.5% |
| Q4 2025 | Sep 16, 2025 | +9.7% |
| Quarter to Mar 31, 2025 | May 28, 2025 | −8.0% |
| Q2 2025 | Feb 28, 2025 · Before open | 0.0% |
| Q1 2025 | Nov 27, 2024 | +7.1% |
| Q4 2024 | Aug 29, 2024 | +12.1% |
| Q3 2024 | Apr 15, 2024 · Before open | −2.1% |
| Q2 2024 | Feb 29, 2024 · Before open | +16.1% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Nov 29, 2023 | +2.8% |
| Q4 2023 | Aug 30, 2023 · After close | 0.0% |
| Q3 2023 | May 31, 2023 | −3.6% |
| Q2 2023 | Feb 28, 2023 · Before open | −3.7% |
| Q1 2023 | Nov 30, 2022 | +4.5% |
| Q4 2022 | Aug 30, 2022 · After close | −8.6% |
| Q2 2022 | Feb 27, 2022 · After close | −2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 38 slides | October 2026 |
| Investor Presentation (July 2026) | Investor deck | 31 slides | Jul 24, 2026 |
| Investor Presentation (June 2026) | Investor deck | 41 slides | June 2026 |
| Investor Presentation (December 2025) | Investor deck | 60 slides | December 2025 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 22 slides | Nov 20, 2025 |
| Investor Presentation (November 2025) | Investor deck | 60 slides | Nov 1, 2025 |
| Investor Presentation (October 2025) | Investor deck | 54 slides | Oct 20, 2025 |
| Corporate Update (October 2025) | Corporate update | 43 slides | Oct 20, 2025 |
| Investor Presentation (August 2025) | Investor deck | 61 slides | August 2025 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 12 slides | Nov 25, 2024 |
All 28 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Share purchase plan of sPP Shares with SPP Attaching Options Closed: A$3M raised · A$0.009 a share · Warrants at A$0.018 Buyers: Trading Capital Management (HK) Ltd (~A$1.5 million pursuant to a shortfall commitment) Insiders: ~A$0.1 million subscribed by participating Directors Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes | Sep 17, 2026 | US$2.13M |
| Registered direct offering of american Depositary Shares with unregistered warrants Announced: about US$4.1M · US$3.16 a share · Warrants at US$3.79 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes | Jul 27, 2026 | |
| Private placement of ordinary shares with attaching options Announced: about A$6.7M · Warrants at A$0.018 Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes | Jul 27, 2026 | US$4.68M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.77M | 3.63M | 299.2K | 292.4K | 8.83K | 0 |
| Cost of revenue | 4.92M | 3.59M | 2.98M | |||
| Gross profit | -2.15M | 39.3K | 299.2K | 292.4K | -2.97M | |
| Research and development | 50.0M | 27.5M | 23.1M | 22.6M | 7.49M | |
| Selling, general and administrative | 18.6M | 12.4M | 300.6K | |||
| Operating income | -68.3M | -38.2M | -47.2M | -34.5M | -19.9M | -484.8K |
| Depreciation and amortization | 7.33K | 2.60M | 3.13M | 3.30M | 2.98M | 1.16M |
| EBITDA | -68.3M | -35.6M | -44.1M | -31.2M | -16.9M | 678.7K |
| Interest expense | 112.4K | 65.3K | 642.9K | 86.1K | 9.35M | 0 |
| Income before tax | -56.9M | -38.2M | -47.9M | -34.6M | -30.3M | -485.2K |
| Income tax | -54.4K | 103.3K | 96.4K | 38.0K | 44.4K | -1.16M |
| Net income | -55.1M | -38.3M | -47.9M | -34.6M | -30.3M | -485.2K |
| Earnings per share, basic | -0.02 | -1.76 | -12.41 | -11.32 | -0.11 | -0.00 |
| Earnings per share, diluted | -1.76 | -12.41 | -11.32 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 4.14M | 29.1M | 18.6M | 11.7M | 27.0M | 27.1K |
| Receivables | 17.4M | 10.4M | 987.4K | 4.47M | 56.5K | 6.35K |
| Inventory | 1 | -6.35K | ||||
| Current assets | 21.9M | 39.9M | 22.8M | 27.3M | 33.4K | |
| Property, plant and equipment | 53.5K | 60.8K | 1.58K | |||
| Total assets | 60.1M | 86.5M | 72.0M | 83.4M | 33.4K | |
| Accounts payable | 5.47M | 9.34M | 10.9M | 5.12M | 1.19M | 64.4K |
| Current liabilities | 18.9M | 14.9M | 17.6M | 7.88M | 158.1K | |
| Total debt | 59.0K | |||||
| Total liabilities | 37.8M | 43.6M | 44.7M | 20.4M | 158.1K | |
| Shareholders' equity | 24.7M | 42.9M | 27.4M | 45.6M | 63.0M | -124.7K |
| Shares outstanding | 3.54B | 279.8M | 277.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Cash from operations | -52.8M | -36.6M | -23.0M | -23.2M | -9.91M | -32.9K |
| Capital spending | -52.8M | -45.3K | -28.3M | -1 | ||
| Free cash flow | -52.8M | -23.2M | -38.2M | -32.9K | ||
| Cash from investing | -5.42M | 1.77M | -320.0K | -1.53M | -28.4M | -28.4M |
| Cash from financing | 33.4M | 45.4M | 30.2M | 9.22M | 65.1M | 60.0K |
| Share buybacks | -4.83M | 1.00K | ||||
| Change in cash | -25.0M | 10.6M | 6.90M | -15.5M | 27.0M | 27.1K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| RAD interim analysis at SNO26 on RAD101 Phase IIb data | Nov 15, 2026 | Other filings | ASX |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| Change of Director's Interest Notices x 4 | Nov 10, 2026 | Ownership change notice | ASX |
| 6-K · Report of a foreign issuer | Nov 4, 2026 | Current report | SEC |
| RAD Alignment with US FDA for Development of RAD101 | Nov 3, 2026 | Other filings | ASX |
| 6-K · Report of a foreign issuer | Oct 30, 2026 | Current report | SEC |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
Show 200 filings
This page holds 200 of 290 filings. Open Filings
Cap table
Built by 6ix from Radiopharm Theranostics Limited’s releases · as of Sep 17, 2026
- Common shares
- 4,377,549,491
- Fully diluted
- 4,377,549,491
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 4,377,549,491 |
Warrants and options
| Lot |
|---|
| Warrants · A$0.018 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 4,377,549,491 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Aaron Laurita Other companies: Immuron Limited (Chief Financial Officer · Since at least Feb 9, 2026) | Chief Financial Officer · Since at least Mar 18, 2026 |
| Dimitris Voliotis Other companies: Zentalis Pharmaceuticals, Inc. (SVP, Clinical Development · Apr 3, 2020 – Feb 10, 2022 · Past) | Chief Medical Officer · Since at least Mar 18, 2026 |
| Noel Donnelly Other companies: PepGen Inc. (Chief Financial Officer · Since at least May 5, 2022) | Director · Since at least Mar 18, 2026 |
| Barbara Lani | VP Quality Affairs · Since at least Nov 5, 2026 |
| Bruce Michael Goodwin | Director · Since at least Mar 18, 2026 |
| Donna Supko | VP Regulatory Affairs · Since at least Nov 4, 2026 |
| Emily Love-Leon | VP Clinical Operations · Since at least Nov 4, 2026 |
| Hester Larkin | Non - Executive Director · Since at least Mar 18, 2026 |
| Hitesh Goel | Head of Project Management · Since at least Nov 5, 2026 |
| Ian Turner | Non - Executive Director · Since at least Mar 18, 2026 |
All 17 people
| Person | Seat |
|---|---|
| John M. Viglotti | SVP Corporate Services · Nov 5, 2025 – Nov 5, 2026 · Past |
| Levente Meszaros | VP Preclinical and Translational Science · Since at least Nov 5, 2026 |
| Melissa Thomas | VP Portfolio Program Lead · Since at least Nov 5, 2026 |
| Paul Hopper | Executive Chairman · Since at least Mar 18, 2026 |
| Riccardo Canevari | Managing Director and CEO · Since at least Mar 18, 2026 |
| Sherin Al-Safadi | VP Medical and Corporate Affairs · Since at least Nov 5, 2026 |
| Vimal Patel | VP CMC · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Radiopharm Theranostics Limited.